Association between HIV type 1-specific T cell responses and CD4 + T cell counts or CD4+:CD8+ T cell ratios in HIV type 1 subtype B infection in China

AIDS Research and Human Retroviruses

Volumn 22, Issue 8, 2006, Pages 780-787

  Wang, Shaoyang ^a   Zhuang, Yan ^a   Zhai, Song ^a   Zhao, Shuguang ^a   Kang, Whenzhen ^a   Li, Xinhong ^a   Yu, Xu G ^b   Walker, Bruce D ^b   Altfeld, Marcus A ^b   Sun, Yongtao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAG PROTEIN; POL PROTEIN; PROTEIN P17; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MATRIX PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS TYPE 1;

ADULT; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHINA; CLADISTICS; CLINICAL ARTICLE; CONSENSUS SEQUENCE; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1B; HUMAN IMMUNODEFICIENCY VIRUS 1C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; VACCINATION; ADOLESCENT; CLASSIFICATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SPECIES DIFFERENCE; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CHINA; FEMALE; GENE PRODUCTS, GAG; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; SPECIES SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; VIRAL PROTEINS;

EID: 33748741194     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.780     Document Type: Article

References (41)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
2. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, and Borkowsky W: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
3. Ogg GS, Kostense S, Klein MR, Jurriaans S, Hamann D, and McMichael AJ: Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression. J Virol 1999;73:9153-9160.
4. + T-cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-998.
5. + T lymphocytes. Science 1999;283:857-860.
6. Rinaldo C, Huang XL, Fan Z, Ding M, Beltz L, and Logar A: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J Virol 1995;69:5838-5842.
7. Copeland FK and Heeney JL: T-helper cell activation and human retroviral pathogenesis. Microbiol Rev 1996;60:722-742.
8. + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992;175:331-340.
9. + T cell responses associated with control of viremia. Science 1997;278:1447-1450.
10. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000;82:792-798.
11. Novitsky V, Gilbert P, Peter T, McLane MF, Gaolekwe S, and Rybak N: Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 2003;77:882-890.
12. Bouscarat F, Levacher-Clergeot M, and Dazza MC: Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type1. AIDS Res Hum Retroviruses 1996;12:17-24.
13. Chun TW, Justement JS, Pandya P, Hallahan CW, McLaughlin M, Liu S, and Ehler LA: Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 2002;185:1672-1676.
14. Bonnet F, Thiebaut R, Chene G, Neau D, Pellegrin JL, Mercie P, Beylot J, Dabis F, Salamon R, and Morlat P: Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Med 2005;6:198-205.
15. Shakoor Z: Serial evaluation of percentage of activated T-lymphocytes in peripheral blood of human immunodeficiency virus infected individuals as a prognostic marker. Saudi Med J. 2003;24:632-636.
16. Wayne PA: National Committee for Clinical Laboratory Standards. Clinical applications of flow cytometry: Quality assurance and immunophenotyping of lymphocytes; approved guideline. 1998; NCCLS document H42-A (vol. 18, no. 21).
17. Wayne PA: National Committee for Clinical Laboratory Standards. Procedures for the collection of diagnostic blood specimens by venipuncture; approved standard-fourth edition. 1998; NCCLS document H3A4 (vol 18, no. 7).
18. Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N, Annamalai K, Vogel TU, Hammond M, Bunce M, Coovadia MN, and Walker BD: Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by ELISPOT and intracellular cytokine staining assays. J Virol 2001;75:1339-1347.
19. Li GH, Chen ZW, Chen Z, Wei FL, Mei S, and Huang YX: Study on the distribution of human immunodeficiency virus-1 subtypes in different regions of China and mother-to-child transmission. Zhonghua Liu Xing Bing Xue Za Zhi 2004;25:1013-1018 (Chinese).
20. Zheng X, Wang Z, Xu J, Huang S, Wang C, Li Z, Wang L, Zhang G, Gao M: The epidemiological study of HIV infection among paid blood donors in one county of China. Zhonghua Liu Xing Bing Xue Za Zhi 2000;21:253-255 (Chinese).
21. Novitsky V, Flores-Villanueva PO, Chigwedere P, Gaolekwe S, Bussman H, and Sebetso G: Identification of most frequent HLA class I antigen specificities in Botswana: Relevance for HIV vaccine design. Hum Immunol 2001;62:146-156.
22. Ganusov VV: The role of the cytotoxic T-lymphocyte response and virus cytopathogenicity in the virus decline during antiviral therapy. Proc Biol Sci 2003;270:1513-1518.
23. Kuiken CL: A compilation and analysis of nucleic acid and amino acid sequences. In: Human Retroviruses and AIDS 1999. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 1999.
24. Novitsky V, Rybak N, Mclane MF, Gilbert P, Chigwedere P, and Essex M: Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific Elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001;75:9210-9228.
25. Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, and Annamalai K: Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med 2000;192:1819-1832.
26. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, and Sullivan JL: Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T-cell loss: Evidence supporting a protective role for CTL in vivo. J Infect Dis 1997;176:118-125.
27. Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, and Annamalai K: Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med 2000;192:1819-1832.
28. Price DA, Goulder PJ, Sewell AK, Easterbrook PJ, and Troop M: Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997;94:1890-1895.
29. Ranki A, Lagerstedt A, Ovod V, Aavik E, and Krohn KJ: Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch Virol 1994;139:365-378.
30. Collins KL, Chen BK., Kalams SA, Walker BD, and Baltimore D: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391:397-401.
31. Schwartz O, Marechal V, Le Gall S, Lemonnier F, and Heard JM: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996;2:338-342.
32. Fukada K, Tomiyama H, and Chujoh Y: HLA-A_1101-restricted CTL recognition for a novel epitope derived from the HIV-1 Env protein. AIDS 1999;13:2597-2599.
33. Fukada K, Chujoh Y, and Tomiyama H: HLA-A_1101-restricted CTL recognition of HIV-1 Pol protein. AIDS 1999;13:1413-1414.
34. Bond KB, Sriwanthana B, Hodge TW, De Groot AS, Mastro TD, and Young NL: An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res Hum Retroviruses 2001;17:703-717.
35. Clayton J, Lonjon C, and Whittle D: Allele and haplotype frequencies for HLA loci in various ethnic group. In: HLA (Charron D, ed.), Volume I: Genetic Diversity of HLA Functional and Medical Implication. EDK Medical and Scientific International Publishers, Paris, 1997, pp. 665-670.
36. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, and Stephens HA: HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. AIDS Res Hum Retroviruses 2001;17:719-734.
37. Gruters RA, Van Baalen CA, and Osterhaus AD: The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 2002;20:2011-2015.
38. Van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, and De Wolf F: Human immunodeficiency virus type-1 Rev- and Tat-specific cytotoxic T-lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997;78: 1913-1918.
39. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, and Habeeb K: The HIV controller study collaboration: The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T-lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001;98:1781-1786.
40. Huyen C, Phyllis K, Jean-Louis S, Abdoulaye D, and Gailp P: Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997;71:8615-8623.
41. Deniz D, Jacques M, Franck L, Doris S, Neliy G, and Marc D: Cross-reactions between the cytotoxic T-Lymphocyte responses of human immunodeficiency virus-infected African and European patients. J Virol 1998;72:3547-3553.